Akeso Inc. has announced the enrollment of the first patient in its Phase III clinical trial (AK112-312/HARMONi-GI6) evaluating the efficacy of ivonescimab as a first-line treatment for advanced metastatic colorectal cancer. This trial is a pivotal step in addressing the unmet clinical needs for patients with this condition. Previous Phase II data, presented at the 2024 European Society for Medical Oncology Congress, demonstrated promising anti-tumor activity of ivonescimab in combination with chemotherapy, showing an overall response rate of 81.8% and a disease control rate of 100%. The ongoing Phase III trial aims to further validate these findings and potentially offer a novel immunotherapy treatment option for patients with microsatellite stable or proficient mismatch repair-type metastatic colorectal cancer, a group representing up to 95% of such cases.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。